Citi Starts Ascendis Pharma (ASND) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $251.27 -0.68%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Citi analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Buy rating and a price target of $187.00.
For an analyst ratings summary and ratings history on Ascendis Pharma click here. For more ratings news on Ascendis Pharma click here.
Shares of Ascendis Pharma closed at $108.52 yesterday.
You May Also Be Interested In
- Tigress Financial Partners Resumes Southwest (LUV) at Buy
- Jefferies Starts AbCellera Biologics (ABCL) at Buy
- Canaccord Starts Ascendis Pharma (ASND) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
